Skip to content
Candid Therapeutics
-
UCB expands autoimmune pipeline with US$2.2B Candid Therapeutics acquisition
The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.